Shutter-speed pharmacokinetic analysis of dynamic-contrast-enhanced (DCE)-MRI data allows evaluation of equilibrium inter-compartmental water interchange kinetics. The process measured here -transcytolemmal water exchange -is characterized by the mean intracellular water molecule lifetime (τ i ). The τ i biomarker is a true intensive property not accessible by any formulation of the tracer pharmacokinetic paradigm, which inherently assumes it is effectively zero when applied to DCE-MRI. We present population-averaged in vivo human breast whole tumor τ i changes induced by therapy, along with those of other pharmacokinetic parameters. In responding patients, the DCE parameters change significantly after only one neoadjuvant chemotherapy cycle: while K trans (measuring mostly contrast agent (CA) extravasation) and k ep (CA intravasation rate constant) decrease, τ i increases. However, highresolution, (1 mm) 2 , parametric maps exhibit significant intratumor heterogeneity, which is lost by averaging. A typical 400 ms τ i value means a trans-membrane water cycling flux of 10 13 H 2 O molecules s À1 /cell for a 12 μm diameter cell. Analyses of intratumor variations (and therapy-induced changes) of τ i in combination with concomitant changes of v e (extracellular volume fraction) indicate that the former are dominated by alterations of the equilibrium cell membrane water permeability coefficient, P W , not of cell size. These can be interpreted in light of literature results showing that τ i changes are dominated by a P W (active) component that reciprocally reflects the membrane driving P-type ATPase ion pump turnover. For mammalian cells, this is the Na Keywords: maps; intratumor; heterogeneity; metabolic activity; therapy
INTRODUCTION Tumor heterogeneity
Cell type and metabolic heterogeneity are crucial tissue characteristics. For example, there is much current interest in intratumor phylogenetic diversity. Its metabolic consequences are likely of great significance in therapy resistance or tolerance (1) (2) (3) (4) (5) (6) . This heterogeneity presents a challenge to blood tests, point biopsies, and ex vivo tissue homogenization, and puts a premium on in vivo assessment with the highest possible spatial resolution and on an individual-by-individual basis (7) . The most feasible current methods of human metabolic imaging, 18 F positron emission tomography (8) and hyperpolarized 13 C magnetic resonance spectroscopic imaging (9) , are extremely informative, but generally have insufficient resolution (typically 5 and 7 mm, respectively) to clinically assay intratumor heterogeneity, and are costly. In contrast, water hydrogen proton ( 1 H 2 O) MRI affords millimeter or sub-millimeter spatial resolution in human studies, uses no ionizing radiation, is minimally invasive, and is relatively inexpensive. Though millimeter or sub-millimeter does not match the resolution of histopathology microscopy, it detects considerable intratumor heterogeneity. Conventionally, however, 1 H 2 O MRI is thought to provide only anatomical/vascular (and sometimes tissue functional) information. Fortunately, a new opportunity is presenting itself. It arises from the ability of MR to measure intercompartmental water molecule exchange kinetics. This study investigates the implications of the heterogeneity of such trans-cytolemmal kinetics within malignant human breast tumors before and after neoadjuvant chemotherapy (NACT).
BACKGROUND Mean intracellular water molecule lifetime (τ i )
The kinetics of the equilibrium (steady-state) exchange of water molecules across cell membranes have been studied by isotope labeling techniques for almost 60 years (reviewed in (10) ) and by NMR methods for over 40 years (reviewed in (11) (12) (13) ). For a 'wellmixed' cytoplasm, the kinetics can be expressed in Equation [1] :
where τ i is the mean lifetime of a water molecule inside the cell, P W the cell membrane water permeability coefficient, and (A/V) the claustrophobia ratio (A is the individual cell surface area and V the individual cell volume) (14) . The NMR community tends to report τ i values (11) (12) (13) while the isotope community gives P W values: P W is often labeled P d , the diffusive permeability (10) . (We note that, even though they have the same dimensions (distance/time), P W [≡ P d ] is not the same as P f , the water permeability coefficient in the presence of a transmural osmotic gradient, which causes net trans-membrane water transport ('flow') simultaneous with the much faster exchange (15) (16) (17) .) Using Equation [1] , one finds published P W and τ i values to be in general agreement (13) . The τ i reciprocal, τ i
À1
, is the unidirectional first-order rate constant, k io , for equilibrium water efflux from the cell -there is no net [2] transport (18) . Values of τ i À1 span four orders of magnitude -the extremes range from 10 À2 s À1 for Xenopus oocytes to 10 2 s À1 for erythrocytes (11) (12) (13) 19) . For virtually all other cells, however, τ i values are hundreds of milliseconds and the 'well-mixed' approximation is quite good (20) . For only the very largest, e.g. the Xenopus oocyte (1 mm diameter), does this condition just begin to fail (19) . Equation [1] can be approximated with Equation [3] :
where C is a constant shape factor and d the cell diameter. If the cell is spherically shaped, C = 6 (if the cell shape is well approximated as a right cylinder, C = 4). The quantity d is a one-dimensional (1D) measure of cell size. There has been some recent concern (21) that interpretation of literature data on the blood wash-out following bolus injections of isotopically labeled water implies cerebral cortical τ i ≥ 30
s. This is almost two orders of magnitude greater than values generally found (10) (11) (12) (13) . Taking a typical value of P W = 1.4 × 10 À4 cm s À1 (10), a τ i of 30 s in Equation [3] yields a d value of 250 μm:
clearly much larger than the average cell (6) . A simple tracer intravasation interpretation of the same blood wash-out data yields (22) a mean lifetime for extravascular water (τ exv ) of 21 s -in good agreement with the blood capillary water permeability coefficient from isotopically labeled water experiments. Seemingly, τ exv has been mis-assigned as τ i in (21) .
Active trans-membrane water cycling
The equilibrium water exchange process has been conceived as resulting from passive molecular mechanisms: simple diffusion across the lipid bilayer, passage through aquaporin membrane protein channels, leakage through membrane transporters, etc. (23) (24) (25) . Changes in d (or C) -cellular swelling or shrinking (edema) -will alter τ i
À1
. However, the rate constant for d change is at least an order of magnitude smaller than τ i À1 (k io ) itself (15, 17) . Any τ i
changes not due to d (or C) alterations must be due to changes in P W , which has always been thought of as a passive cell membrane property (P W (passive)). However, NMR studies have recently revealed an active component (P W (active)) much larger than the passive contribution (17) . This is due to active trans-membrane water cycling that accompanies active trans-membrane osmolyte cycling, which is paced by the driving cell membrane P-type ATPase ion pump (17) . For mammalian cells, this is the Na + ,K + -ATPase, NKA (17, (26) (27) (28) . The existence of this water cycling is significant.
NMR principles
The classic NMR measurements are mostly of homogeneous cell suspensions. The presence of an extracellular paramagnetic contrast agent (CA) increases the intrinsic longitudinal relaxation rate constant R 1o (≡ (T 1o ) À1 ) of the outside water proton signal
. Though the term was introduced only in 1999 (29) , this approach increases the longitudinal 'shutter-speed,'
sufficiently that the water exchange NMR system is moved out of the fast-exchange-limit (FXL) condition (R 1i is the intrinsic intracellular relaxation rate constant). A sufficient outside CA concentration, [CA o ], allows the NMR system to reach the slow-exchange-regime (SXR) condition. This is characterized by non-mono-exponential longitudinal magnetization recovery, but is distinct from the slow-exchange-limit and no-exchangelimit conditions (13, 17, 22, 29, 30) . It is quite common to achieve the SXR with cell suspensions (11) (12) (13) 17, 22 (11, 12) ).
Dynamic-contrast-enhanced (DCE)-MRI
The spatial encoding of 1 H 2 O in MRI offers the possibility of measuring, and mapping, τ i values in human biological tissues in vivo. A stepped CA infusion producing incremental plasma and interstitial CA steady-state levels works well in animal models (29) , but is impractical for human use. However, in the common clinical DCE-MRI approach, serial T 1 -weighted 1 H 2 O images are obtained before, during, and after a bolus CA injection. The timecourse of the CA bolus passage through the field of view is measured. The shutter-speed concept can be incorporated into the pharmacokinetic analysis of the time-course. This differs from the tracer pharmacokinetic paradigm, which is based on the fact that compartmentalization is not encoded in the tracer signal: it does not distinguish compartments entered by tracer. In DCE-MRI, CA compartmentalization is intrinsic to the 1 H 2 O signal, which continuously tracks the amounts of H 2 O and CA in each compartment. Thus, imposition of a classic tracer analysis on DCE-MRI data joins these contradictory postulates about CA compartmentalization, and the only reconciliation is the inherent and incorrect assumption that the NMR system is always in the FXL condition, i.e., that τ i is effectively zero. Thus, besides systematically distorting the values of other pharmacokinetic parameters, this renders τ i À1 inaccessible. For a recent detailed overview, see (30) . Immediately after a bolus intravenous (IV) injection, in almost all tissues CA transiently extravasates and NMR systems transiently depart the FXL for the FXR condition. There is no evidence that, with CA doses approved for human subjects, any system ever reaches the SXR condition (13, 30) . However, the interstitial CA concentration, [CA o ] (and thus т 1
À1
), value varies naturally -increasing and decreasing during the DCE time-course.
Using the shutter-speed pharmacokinetic paradigm (SSP), we (30, (32) (33) (34) (35) (36) (37) (38) (39) (40) and others (41) (42) (43) (44) (45) have presented high-resolution, pixel-by-pixel, τ i maps. Importantly, the τ i magnitudes in the maps, and averaged over regions of interest (ROIs), are in general agreement with those from the many, precise NMR spectroscopic cell suspension measurements (11) (12) (13) . This indicates that in vivo τ i accuracy is reasonable.
Let us consider fundamental aspects of the DCE pharmacokinetic parameters as biomarkers. The K trans quantity , mainly a rate constant for capillary CA extravasation/tissue arrival, is elaborated in Equation [4] :
k ep is the first-order rate constant for CA intravasation, v e the CA distribution volume (mainly the extracellular, extravascular volume fraction), k pe the rate constant for CA extravasation, v p the blood plasma volume fraction, P CA the capillary wall CA permeability coefficient, and S the total blood capillary surface area (13, 18, 30, 34, 35, 46) . The v e , v p , and S magnitudes depend on the extent of voxel or ROI cell density (for v e ) or capillary density (for v p or S) magnitudes. Thus, though the K trans , v e , and v p biomarkers are formally intensive quantities, their values reflect the numbers of cells or capillaries. The τ i parameter, on the other hand, is a true intensive property. For spherical cells, Equation [3] yields τ i = 0.17(d/P W ), where d and P W represent, respectively, the mean voxel or ROI cell diameter and cytolemmal water permeability coefficient. The τ i magnitude does not depend on the extent of the voxel or ROI cell density (ρ) value: τ i is independent of v e , or the intracellular volume fraction, v i (≈ (1 -v e ) ). This is an important, and novel, characteristic for an imaging biomarker.
EXPERIMENTAL Subjects
We report on a cohort of 11 consecutive women undergoing NACT for locally advanced breast cancer diagnosed by core needle biopsy. The six-cycle therapeutic course was TP 0 -[
where TP is therapy point. Each three-week cycle comprised a single IV infusion of a drug cocktail. As per standard care, surgeries (seven mastectomies, four lumpectomies) followed TP 3 -after 18 weeks of therapy. Pathology analyses of the surgical specimens are described below. The subjects underwent DCE-MRI studies at TP 0 , TP 1 , TP 2 , and TP 3 . In each case, DCE parameters were spatially averaged and/or computed pixel by pixel, and the results compared with pathology findings.
Two representative cases were selected for high-resolution parametric mapping and in-depth deductive analyses. In each of these, the tumor was a grade 2 invasive ductal carcinoma (IDC) and the patient was HER2 (human epidermal growth factor receptor 2) positive and BRCA1/BRCA2 mutation negative. One was determined a non-complete responder by pathology (nonpCR). (She is estrogen (ER) and progesterone (PR) receptor negative but has a family history of breast cancer.) Her NACT comprised a trastuzumab (monoclonal antibody interfering with HER2/neu receptor), docetaxel (anti-mitotic interfering with microtubules), and carboplatin (interferes with DNA repair) cocktail for each cycle. The other was determined a complete responder (pCR). (She is ER (100%) and PR (10%, focal) positive.) Her NACT comprised a trastuzumab and paclitaxel (anti-mitotic interfering with microtubules) cocktail for the first three cycles. Six weeks after our TP 1 study of the pCR subject (i.e. after three NACT cycles), her therapy was switched to a cyclophosphamide (alkylating DNA interference) and Adriamycin (DNA intercalating) cocktail for the last three cycles.
DCE-MRI
The protocol was approved by the local Institutional Review Board. With informed consent, the patients participated in this ongoing MRI research study, which played no role in their clinical management. We have reported extensive details on DCE-MRI data acquisition from the breast (13, 18, 45, 46) and prostate (30, 47) . Here, axial bilateral DCE-MRI images with fat saturation and full breast coverage were acquired with a 3D gradient echo-based time-resolved angiography with stochastic trajectories sequence (45) using a Siemens 3 T instrument. DCE-MRI acquisition parameters included 10 o flip angle, 2.9/6.2 ms T E /T R , a parallel imaging acceleration factor of two, (30-34 cm) 2 FOV, (320) 2 matrix size, and nominal 1.4 mm slice thickness. The nominal in-plane resolution was (1.1 mm) 2 . This yielded a nominal 1.7 μL voxel. The total acquisition time was~10 min for 32-34 image volume sets with 18-20 s temporal resolution. The CA Gd(HP-DO3A) (ProHance) IV injection -0.1 mmol kg À1 (the clinical single dose) at 2 mL s À1 -was carried out following acquisition of two baseline image volumes. A population-averaged arterial input function was obtained from axillary arteries (13, 18, 46) . We used the FXR-allowed SSP version -detailed in (30) -for analyses of spatially averaged and pixel-by-pixel DCE-MRI time-course data. These were subjected to both tracer and shutter-speed pharmacokinetic analyses to extract the K trans , v e , k ep (= K trans /v e ), and τ i (SSP only) DCE parameters. Our focus is mostly on high-resolution parametric maps. However, there is some spatial averaging. These tumors are sufficiently heterogeneous that the averaging method must be specified. The averaged before pharmacokinetic analysis. For (c) 'image slice pixel-averaged' data, the individual pixel time-courses are analyzed and then the resulting parameters averaged.
Parameter precision from Monte Carlo simulations
For the pCR subject selected for in-depth analyses, the precision of fitted DCE parameters (τ i and K trans ) was estimated using a Monte Carlo approach detailed previously (48) . The DCE-MRI time-courses for each tumor pixel in the chosen image slice, obtained at both TP 0 and at TP 1 , were analyzed. Six fittings of each voxel DCE-MRI time-course were made, starting with randomly different initial sets of parameter values spanning broad ranges. The standard deviations (SDs) of the returned parameter values were calculated.
Histology
The response to NACT for each patient was determined by pathology analysis of post-therapy surgical specimens (after TP 3 ) and comparison with pre-therapy biopsy specimens (before TP 0 ). This comprised the determination of the residual cancer burden (RCB) and the relative change in tumor cell density using published methods (49, 50) . These analyses revealed that three patients were pCR -no cancer cells found in resection specimens -while the other eight were non-pCR -reduced cancer cell density in resection specimens compared with biopsy specimens. For the nonpCR case selected for in-depth analysis, a whole-mount slide of a slice of a biopsy core obtained pre-therapy (before TP 0 ) was used to estimate the extent of necrosis and the cell densities in regions of the parametric tumor rim and tumor core. The biopsy core was obtained with a 14 gauge needle (1.6 mm ID), inserted from medial to lateral, and the hematoxylin and eosin (H&E)-stained slide was examined by microscopy at both low and high power (200×).
Statistical analyses
Tumor ROIs were drawn by experienced radiologists, who also measured the largest 1D tumor size according to the RECIST (Response Evaluation Criteria in Solid Tumors Group) (51) guideline.
The results from pathology analyses were correlated with the MRI metrics using the ULR (univariate logistic regression) analysis in order to identify imaging biomarkers for early prediction of response and/or accurate assessment of residual disease following NACT.
RESULTS

Human breast cancer and therapy
We have presented many DCE time-courses of breast (13, 18, 46) and prostate (30, 47) cancer data. Figure 1 displays whole breast axial DCE image slices obtained during CA passage for two subjects with IDC representative of the population here -one found a nonpCR ( Fig. 1(a) , (c); left breast) and one a pCR ( Fig. 1 ; τ i in s) are given; v e is dimensionless. We briefly divert to spatial-and population-averaged results. are RECIST, K trans (tracer), K trans (SSP), k ep (tracer), k ep (SSP), and τ i . The vertical axis measures the percentage change in the biomarker after the first NACT cycle, i.e. in the three weeks between TP 0 and TP 1 . The bar color (pCR versus non-pCR), however, is determined only after completion of the entire NACT therapeutic course (18 weeks), surgery, and pathology analyses. Though the mean tumor size (RECIST) decreased only slightly after three weeks, the DCE biomarkers showed larger changes. Interestingly, the SSP K trans and k ep parameters decreased for the pCR subpopulation, while τ i increased. Overall, the ULR analysis found that the percentage changes in tumor mean K trans (tracer and SSP), k ep (tracer and SSP), and pixel τ i histogram median after the first NACT cycle (at TP 1 relative to TP 0 ) were excellent discriminators of pCRs from non-pCRs, each with the ULR c statistic value of 1.0 (meaning complete separation), while the early RECIST percentage change was a poor predictor with c = 0.60. (The v e parameter has c values less than unity.) In addition, the absolute values of TP 1 tumor mean K trans (SSP) and k ep (tracer and SSP) were also effective (c = 1.0) early discriminators (not shown). After only one NACT cycle, changes in the tumor-averaged shutter-speed DCE biomarkers K trans , k ep , and τ i are excellent predictors of the therapeutic outcome to be found after NACT completion. This is very encouraging. We have published a preliminary report with more results (40) , and plan a full paper on these aspects. The tumor-averaged K trans (SSP) and τ i values at TP 3 significantly correlate with the RCB magnitude found by pathology analyses.
However, the significant intra-and intertumor heterogeneity (1-6) described above seriously calls for individualized tumor assessment (7) . For the remainder of this paper, we return our focus to the intratumor parametric maps of the two representative Figure 1 , 2 case studies. These allow in-depth deductive analyses of τ i interpretation. In these, the subjects serve as their own controls. Figure 4 shows τ i (ordinate), K trans (abscissa) scatter plots of the 228 tumor pixels from Figures 2(g), (i) (0.38 mL ROI) (a) and the 142 tumor pixels from 2(j), (l) (0.24 mL ROI) (b). These are for the representative pCR patient. The τ i values in NMR spectroscopic cell suspension studies and in ROIs can be determined with precisions better than 5% (17) and 10% (30) , respectively. However, single voxel DCE-MRI data have greater relative noise, which could diminish pixel τ i precision. Figure 4 (48) . All error bars are present: many are smaller than the circles. In these cases, the τ i precision seems comparable to, or better than, that of cell suspension studies. But some fitting uncertainties are larger. Inspection of Figure 4 (a) shows, however, that these occur only in regions where K trans is relatively small. In these cases, [CR o ] and thus the shutter speed (т 1 À1 ) does not become very large for very long, and the system does not depart the FXL for the FXR condition very extensively and/or for a very long duration (13, 30, 32) . Interestingly, these greater uncertainties occur for both small and large τ i values. This indicates that τ i precision is not particularly dependent on τ i magnitude (the error bar is relatively independent of the mean). It implies that the τ i accuracy is relatively independent of τ i precision. This is also found for ROI data (30) . The situation in Figure 4 (b) (pCR, TP 1 ; Figure 2 (j)) is different from that in Figure 4(a) . As shown in Figure 3 , the large K trans decrease is good news for the pCR patient. (The tumor image slice-averaged K trans decreases from 0.19 min À1 at TP 0 (Fig. 2(g) ) to 0.04 min À1 at TP 1 ( Fig. 2(j) ) -i.e. by 79%.) However, the greatly diminished K trans provides a difficult scenario for precise τ i determinations. The error bars reflect this. Nonetheless, one can discern that, on the whole, τ i values are larger than in Figure 4 (a). (The tumor image slice pixelaveraged τ i goes from 0.32 s at TP 0 ( Fig. 4(a) ) to 0.39 s at TP 1 ( Fig. 4  (b) ) -a 22% increase.) This result reinforces the notion that the τ i magnitude itself does not decrease with K trans : mostly, the precision of its determination becomes poorer. When clinically indicated, this precision can be considerably improved by moving up to the approved triple CA dose.
A 2D scatter plot is an effective way to take advantage of two responsive biomarkers (52) . The slight negative spatial τ i , K trans correlation apparent to the eye in the Figure 2(g) , (i) parametric maps can also be barely discerned in Figure 4 Figure 2 (i), (l) represents the most conservative of the three pCR cases. Importantly, there are no significant v e differences between core and rim after therapy (Fig. 2(k) ). As we will see, the tumor core τ i increase by therapy is due to a P W decrease.
Parameter heterogeneity, relationships, and therapy responses
Though the tumors appear relatively homogeneous in Figure 1 , the SSP parametric maps exhibit significant intratumor heterogeneity that appears anatomic in nature. For example, the TP 0 K trans maps of each tumor display elevated values in the tumor rim relative to the core. In Figure 2 (a), (g), the K trans variation exceeds a factor of 10. This pattern is common. It is observed in malignant human tumors -breast (37, 46) , osteosarcoma (35) , head and neck (43) , and soft tissue sarcoma (53) , in spontaneous murine breast tumors (39) , and in implanted rodent cerebral gliosarcoma (32), RIF-1 (33) and prostate (38) tumors. However, it is by no means universal: tumors with bright K trans cores (or multiple cores) have been reported for malignant human breast (18, 34, 35, 41, 42) , head and neck (44) , and prostate (47) tumors, and in implanted rat glioma (54) . The observation of this diversity is very promising for individualized imaging.
Furthermore, there are often spatial correlations between the imaging biomarkers. In the Figure 2 (Fig. 2(c) ).) This is also often observed in other human malignant tumors -breast (34, 35, 37) , osteosarcoma (35) , head and neck (43, 44) , and prostate (36) -and in spontaneous murine breast tumors (39) . However, this negative correlation is not always the case: there are counter-examples in the human breast (41, 42) and in implanted rodent gliosarcoma (32, 55) , RIF-1 (33), and prostate (38) tumors. Thus, the sign of the biomarker spatial correlation is independent of the intratumor heterogeneity spatial pattern. For each Figure 2 patient, a comparison of a TP 0 parametric map with that at TP 1 shows the effect of the first NACT cycle. Figure 2 (g), (j) reveals a significant K trans decrease after the first three weeks of therapy for the pCR subject, while there is little, if any, decrease for the non-pCR patient (Fig. 2(a), (d) ). The K trans decrease for the pCR tumor is consistent with the results reported for essentially every antivascular cancer drug tested (56) . Interestingly, the τ i values increase (44% for the tumor image slice-average) for the pCR patient (Fig. 2(i), (l) ; note the more sensitive color scale), but not for the non-pCR individual (Fig. 2  (c), (f) ). Thus, there is a negative τ i , K trans correlation in (therapy) time as well in space. Importantly, the τ i increase and K trans decrease after 3 weeks of NACT predict very well that no RCB will be surgically found after 15 more weeks of therapy. This response is representative of the pCR tumor-and population-averaged results, and occurs usually before significant tumor size decrease (Fig. 3) . This is also true for the K trans decrease caused by therapy on soft tissue sarcoma (53).
We also see τ i increase/K trans decrease after a different therapy on a spontaneous murine breast tumor (39) . It is important to note that the rather large tumor τ i value (0.56 s, image slice average) in Figure 2 (l) is obtained while v e is also very large, 0.87 (image slice average, Figure 2 (k)). If v e is large, then v i (≈1 À v e ) is small. This result reinforces the fact that, contrary to what one might intuit, the τ i magnitude does not decrease with v i . This is because of its intensive nature.
Changes in τ i reflect membrane permeability changes
For globular cells, Equation [3] Let us inspect a τ i variation in Figure 2 . Consider the τ i map of the non-pCR patient at TP 0 (Fig. 2(c) ). We choose an ROI representative of the annular tumor rim: we designate it RN 0 , for rim, non-pCR, at TP 0 . The average τ i value for RN 0 is 0.60 s. For a conservative ROI representative of the outer core, CN 0 , the τ i value is 0.81 s (the inner core has even larger τ i values). These ROIs are outlined with yellow borders in Figure 2( Fig. 2(b) ) and (1 À v e ) ≈ v i ≡ ρV, where v i is the intracellular volume fraction, ρ the mean cell number density, and V the mean individual cell volume (Equation [1] ). For spherical cells, the mean effective cell diameter d′~V 1/3 ≈ {(1 À v e )/ρ} 1/3 . For the Figure 2 (b) RN 0 and CN 0 ROIs (those marked in Fig. 2(c) Figure A1 3D plot shows the trace of all points that simultaneously satisfy both experimental relationships for the non-pCR tumor at TP 0 . If the ρ C /ρ R ratio is determined independently, one can evaluate whether τ i changes are dominated by d changes or by P W changes, or whether both contribute significantly.
To do this, we examined an H&E histology slide of a slice of a biopsy core obtained 24 days before the non-pCR tumor was imaged at TP 0 . The whole mount slide was studied, and microscopic images made at two higher powers. We identified the biopsy core sections corresponding to the 8 mm thick tumor rim and the 5 mm radius tumor core seen in Figure 2 ratio. The conclusion is strong that the 40% increase in τ i À1 measured for the rim over the core ROIs in non-pCR at TP 0 (Fig. 2(c) (Fig. 2(b), (c) ), five other representative ROIs were chosen: RN 1 and CN 1 (Fig. 2(e), (f) ), RC 0 and CC 0 (Fig. 2(h), (i) ), and CC 1 (Fig. 2  (k), (l) ) (in the ROI labels, the first character is R (rim) or C (core), the second character is N (non-pCR) or C (pCR), and the subscript is 0 (TP 0 ) or 1 (TP 1 )). Taken two at a time, these seven ROIs afford 21(= 7!/(5!2!)) ROI pairs and thus 21 Table A1 .) This result is displayed in the Figure 5 column graph. It is very consistent with literature results also compiled and presented in Figure 5 , which summarizes reports of experimentally induced τ i changes that also have accompanying measurements allowing calculation or estimation of d changes. These span three model systems: two cell suspensions (17, 31) and murine myocardium (58) . (Details for these are also given in Table A1 .) Cisplatin treatment induces an apoptotic state in acute myeloid leukemia (AML) cells and elevates τ i À1 by almost 400% (31) . However, the mean d decreases by only 9%. Switching the bubbling gas from N 2 to O 2 increases yeast τ i À1 by 110%, but the mean d decreases by only 7% (17) . For in vivo mouse myocardium, the normal τ i À1 is 130% greater than in chronic hypertension (58), and yet the mean ex vivo cylindrical cardiomyocyte d is decreased by only 23% (58) . It is important to note that two of these studies (31, 58) included microscopy before and after the perturbation. The comparable nature of these model system results and our in vivo human breast tumor findings makes a compelling case that observed τ i À1 variations are dominated by P W changes, not size changes. This is reinforced by the fact that, even though they are of similar (small) size, τ i À1 is~4000% greater for the human erythrocyte (59) than for the yeast cell (17) . It is very fortunate that nature exhibits this phenomenon.
DISCUSSION
As described above, the analysis of DCE-MRI time-course data with any formulation of the tracer pharmacokinetic paradigm (most common by far) is incorrect. It neglects the finite kinetics of the inter-compartmental water exchange equilibria that precede the rate limiting step of CA extravasation. This causes systematic changes in the DCE-MRI pharmacokinetic parameters, K trans and v e . In particular, spatially averaged K trans is disproportionately depressed in malignant tumors of the breast (13, 18, 34, 35, 46) and prostate (30, 47) . The SSP allows extremely high specificity in the detection of these cancers: specificity not possible with tracer analysis. This makes effective cancer detection (13, 18, 34, 46, 47) and therapy prediction (40, 53) practical.
Here, however, we focus on the second benefit of the SSP, access to the water exchange kinetics themselves. This is not possible with the tracer paradigm, where water is not considered molecular but merely a continuum filling tissue compartmental spaces. The equilibrium trans-cytolemmal water exchange kinetics are measured by τ i , the reciprocal of the unidirectional rate constant for water efflux, k io .
Changes in τ i reflect changes in the driving membrane P-type ATPase ion pump turnover
The results above indicate that the intratumor τ i variations observed in human breast cancer are dominated by P W differences. If they were dominated by d, the τ i À1 (k io ) percentage increases and d percentage decreases would be similar. Still, are the differences observed in P W (passive), in P W (active), or in both? Almost all cells have a driving membrane P-type ATPase ion pump enzyme, which serves to generate transmural ion gradients and membrane potentials (26) . For yeast cells, this is the H + -ATPase, Pma1 (17, 26) . For mammalian cells, it is NKA (26). The forward reaction catalyzed by NKA can be written as in Equation [5] , where intracellular adenosine triphosphate (ATP i ) is hydrolyzed to ADP i and P i ,
extracellular potassium (K o + ) is transported into the cell, and intracellular sodium (Na i + ) is expelled. Table 1 summarizes the literature on the dependence of equilibrium transcytolemmal water exchange kinetics (τ i À1 ) on driving membrane P-type ATPase ion pump gene dosage, substrate concentration, and specific inhibitor concentration in yeast suspension, perfused rat heart, (17) , and when hearts in chronically (induced) hypertensive mice were compared with control mice (58) . In this work, 21 pairs of ROIs (in two human breast tumors pre-and post-therapy, Figure 2 (a)-(l)) were compared, always taking the ROI with larger k io as the numerator, and the results averaged. (Details in Table A1 .) The exchange kinetics increases are not dominated by cell size decreases. (17) and NKA (26), respectively.) This is strong evidence that τ i À1 (k io ) is dominated by P W (active), which in turn is driven by P-type ATPase ion pump turnover. The greater the turnover, the faster the exchange. All of these model systems were homeostatic for the Table 1 entries. Figure 6 presents a schematic diagram of the general molecular mechanism we have proposed (17) for active trans-membrane water cycling. The passive water exchange (P W (passive)) equilibrium is indicated at the top right. It involves simple water diffusion through the phospholipid bilayer, transport through aquaporin channels (60, 61) , and leakage through membrane protein transporters (25) . Active trans-membrane water cycling (P W (active)), which can have three times the P W (passive) flux (17), almost certainly involves water co-transporting membrane symporters (24) . In the diagram, active water efflux is pictured as passing through NKA, and influx through the sodium glucose co-transporter (SGLT (62)), but this is only for the purpose of illustration. It is not yet known which symporter molecules dominate active water cycling: there are a number of candidates, SGLT certainly being one of them (24) . By themselves, aquaporins catalyze only passive transmural water transport. However, to the extent to which they co-localize with substrate transporters, say K + channels (60) or NKA (63), they may participate in active trans-membrane water cycling.
Because it maintains the trans-membrane ion gradients that drive much secondary active transport and produce the membrane potential, one can argue that NKA is the most important enzyme in mammalian biology. Because of the particular, dual ('vectorial' and 'scalar' (64)) characteristics of the reaction catalyzed by NKA (Equation [5] ), measurements of its activity have always been adapted to the nature of the sample. For solubilized, purified enzyme or tissue homogenate preparations, one cannot measure the kinetics of (vectorial) ion transport. Thus, spectrophotometric (65) 23 Na, 87 Rb MR spectroscopic (71,72) methods can be used to measure NKA-driven trans-membrane ion transport kinetics. This is how it was learned that, when the concentrations of the other reactants and products have typical values, the intracellular Na + concentration, [Na i + ], is generally the rate-determining factor (71, 73, 74) . It is also possible to measure [Na i + ] using a fluorescent indicator (75) . A breakthrough found that phospholipid vesicles reconstituted with purified NKA facilitated measurement of both ATP hydrolysis and ion transport (66) . This allowed confirmation of the NKA reaction stoichiometry (66) .
It is obvious that each of these methods is best suited to macroscopically homogeneous samples. None are particularly appropriate for use with normally heterogeneous tissue. (NKA distributions can be mapped histologically (76) .) Except for the microelectrode approaches, these do not involve spatial encoding; and one cannot insert electrodes in all of the cells of a tissue. Furthermore, many of these methods directly measure only net NKA activity, not homeostatic NKA turnover.
(An analogous problem arises measuring net versus steady-state water transport kinetics (15) .) A 24 
Na
+ study reveals the existence of an equilibrium transmural Na + exchange process in the cardiomyocyte over an order of magnitude faster than net Na + transport (69) . However, the radioisotope approach has been generally abandoned for~20 years, and deemed too problematic for even tissue preparations (73) . As far as we are aware, the NKA turnover has never been measured, let alone mapped, in a living animal or human subject. Therefore, τ i We show that τ i exhibits significant intratumor heterogeneity in human breast cancer in vivo. That the biomarker spatial correlations are never perfect and that counter-examples exist suggest that, when seen, these are not numerical co-variance artifacts resulting from the three parameter fittings of DCE-MRI data time-courses. They appear to be physiological correlations.
The synergism of two responsive imaging biomarkers can be very powerful. In this case, one reports on kinetic processes occurring outside cells: K trans measures mostly the microvascular CA extravasation/tissue arrival rate. The other (τ i ) measures metabolic fluxes inside cells. Since CA employs a para(endothelial) cellular pathway (77, 78) , it serves also as a surrogate for paracellular extravasation of plasma solutes with similar molecular sizes. Nutrients, particularly glucose (79) , represent a crucial sub-class of these. Though glucose has specific transcellular transporters, when K trans is relatively large it is likely that additional paracellular glucose extravasation is also relatively large. When K trans is relatively large but τ i is relatively small, as in the rims of both Figure 2 tumors before therapy, it may be signaling that greater nutrient delivery enables faster cell metabolism. The pre-therapy biopsy core for non-pCR showed clearly that the parametric rim seen in Figure 2 (a)-(c) corresponds to a band with the greatest density of invasive carcinoma cells and inflammatory lymphocytes. Figure 2 suggests that NACT on the pCR tumor causes rim tissue to move from larger K trans /smaller τ i to smaller K trans /smaller τ i , and core tissue from smaller K trans / smaller τ i to smaller K trans /larger τ i . We find very similar behavior with a different therapy (phosphatase 2A re-activation) on a spontaneous murine breast tumor (39) . Perhaps this pathway is common for therapy-induced tumor regression. The most parsimonious explanation is that a K trans decrease echoes a nutrient delivery decrease and then, subsequently, there is a decrease in metabolic activity signaled as a τ i increase.
The correlation of the results we see at TP 1 with the pathology results after 15 additional weeks of therapy (Fig. 3) is very encouraging. This is crucial for early, personalized therapy evaluation and adjustment. The two cases reported here exemplify this. If we had sufficient statistical experience that our approach informed clinical decisions, the therapy of the non-pCR patient might have been altered after TP 1 , and the therapy of the pCR patient might have been ended after TP 1 , or not switched after TP 3 .
The region of positive τ i , K trans correlation in the rat gliosarcoma rim (32, 55) coincides with the region of the implanted rat glioma that stains positive with EF5 (55,80), a marker for hypoxia. This correlation is also positive for the RIF-1 tumor (33), which is known to be highly hypoxic (81) . New results in a rat model of head and neck cancer show extensive overlap of an elevated τ i region with that of EF5 staining (55) . Also, increased tumor τ i strongly correlates with survival times of human head and neck cancer patients (H. Poptani, personal communication). When τ i is relatively large, the NKA activity is relatively small. Thus, it makes sense that K trans and τ i are large and positively correlated in tissues where the cells may have entered a hypoxic state. Though the delivery of glucose is sufficient, it is not metabolized efficiently w.r.t. ATP synthesis (81, 82) .
The K trans value can be sensitive to the degree of tissue vascularization. If vascularization is low, the apparent K trans value decreases because, after extravasation, CA arrival in the tissue also requires diffusion (83) . We do observe very small K trans and relatively large τ i in breast adipose tissue (34, 35) . Presumably, this is due to the low vascularization. Also, in necrotic areas, one would expect K trans to be relatively small and τ i to be relatively large, since cell metabolism should be slow.
Certainly, the spatial resolution of 1 H 2 O MRI does not compare with that of the optical microscopy of pathology. A typical highresolution MRI pixel covers 4 × 10 6 high power '20 × ' pixels ((0.5 μm)
2 ) from a modern digital pathology microscope (84) . However, the results presented here introduce the potentially highest resolution in vivo metabolic imaging.
APPENDIX A: CHANGES IN τ i REFLECT MEM-BRANE PERMEABILITY CHANGES
Analyses of non-pCR subject pre-therapy RN 0 and CN 0 ROI ( Fig. 2(b) , (c)) parametric relationships Consider the τ i map of the non-pCR patient at TP 0 (Fig. 2(c) ). We choose an ROI representative of the annular tumor rim: we designate it RN 0 , for rim, non-pCR, at TP 0 . The τ i value for RN 0 is 0.60 s. For a conservative ROI representative of the outer core, CN 0 , the τ i value is 0.81 s (the inner core has even larger τ i values). These ROIs are outlined with yellow borders in Figure 2 . Therefore, for an ROI pair labeled R and C, the ratio
. For the Figure 2 
1/3 } = 0.76 must be satisfied.
The red curve in Figure A1 is the trace of all points, in a 3D space of tissue cellular properties, which simultaneously satisfy the experimental . We conclude that P W is substantially larger in the rim of the untreated non-pCR tumor than in the core: τ i variation is not due to d variation.
Other Figure 2 ROIs
Besides RN 0 and CN 0 (Fig. 2(b) , (c)), we have chosen five other representative ROIs: RN 1 and CN 1 (Fig. 2(e) , (f)), RC 0 and CC 0 (Fig. 2(h) , (i)), and CC 1 (Fig. 2(k) , (l)) (in the ROI labels, the first character is R (rim) or C (core), the second character is N (nonpCR) or C (pCR), and the subscript is 0 (TP 0 ) or 1 (TP 1 ) ) range from 0.67 to 1.50, and average 1.05, a 5% increase that is not statistically different from 0%. The details are given in Table A1 . The inter-ROI pair SDs are also given. Since these represent inter-subject and/or inter-session comparisons, their relatively small SD sizes are quite encouraging for the pseudoabsolute nature of these imaging biomarkers.
Literature results
Table A1 also summarizes literature reports of experimentally induced τ i changes that also have accompanying measurements allowing calculation or estimation of d changes. These span Figure A1 . Biomarker inter-relationships for the non-pCR tumor before therapy ( Fig. 2(b three model systems: two cell suspensions (17, 31) and murine myocardium (58) . In the two cell suspension studies, the yeast (17) and AML (31) cell densities were not radically changed by O 2 gasification and cisplatin treatment, respectively. Since the cells are spherical, the ratio of (p i ) À1/3 (where p i is the measured intracellular water mole fraction, 'population') values approximates the (v i ) À1/3 ratio and thus the (d′) À1 ratio. Table A1 shows that the 9% and 10% (d′) À1 increases caused by O 2 gasification of the yeast cells (17) and cisplatin treatment of the AML cells (31), respectively, are much smaller than the concomitant 110% and 390% τ i À1 increases. In the mouse heart, in vivo τ i À1 was observed to decrease after seven weeks treatment with an NO biosynthesis inhibitor, N ω -nitro-L-arginine methyl ester (L-NAME) (58) . The ex vivo fixed tissue (cylindrical) cell d values were microscopically determined for control and L-NAME treated mice. Systematic d errors from tissue fixing must be hard to avoid. As seen in Table A1 , the 130% τ i À1 increase from L-NAME treated to control is accompanied by only a 34% increase in d À1 . The AML study (31) also included microscopy before and after the perturbation. The consistent nature of these model system results and our in vivo human breast tumor findings makes a compelling case that τ i À1 changes are dominated by P W changes.
